These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26086825)

  • 41. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
    van der Straaten RJ; Wessels JA; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Allaart CF; Bogaartz J; Tiller M; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):141-50. PubMed ID: 17286537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients.
    Sandhu A; Ahmad S; Kaur J; Bhatnagar A; Dhawan V; Dhir V
    Clin Rheumatol; 2018 Dec; 37(12):3221-3228. PubMed ID: 30022368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.
    Inoue K; Yuasa H
    Drug Metab Pharmacokinet; 2014; 29(1):12-9. PubMed ID: 24284432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis.
    de Rotte MC; Bulatovic M; Heijstek MW; Jansen G; Heil SG; van Schaik RH; Wulffraat NM; de Jonge R
    J Rheumatol; 2012 Oct; 39(10):2032-40. PubMed ID: 22859359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
    Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V
    Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
    Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project.
    Uribarri M; Ruiz-Larrañaga O; Arteta D; Hernández L; Alcaro MC; Martínez A; Escorza-Treviño S; Estonba A; Migliorini P; Czirják L; del Amo J
    Clin Exp Rheumatol; 2015; 33(5):699-705. PubMed ID: 26314492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs.
    Drozdzik M; Rudas T; Pawlik A; Kurzawski M; Czerny B; Gornik W; Herczynska M
    Eur J Clin Pharmacol; 2006 Nov; 62(11):933-7. PubMed ID: 16932953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
    Majorczyk E; Pawlik A; Kuśnierczyk P
    Int Immunopharmacol; 2010 Dec; 10(12):1626-9. PubMed ID: 20888443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.
    Szostak B; Machaj F; Rosik J; Pawlik A
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):617-626. PubMed ID: 32500745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis.
    Dervieux T; Wessels JA; van der Straaten T; Penrod N; Moore JH; Guchelaar HJ; Kremer JM
    Pharmacogenet Genomics; 2009 Dec; 19(12):935-44. PubMed ID: 19858780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting methotrexate resistance in rheumatoid arthritis patients.
    Yu MB; Firek A; Langridge WHR
    Inflammopharmacology; 2018 Jun; 26(3):699-708. PubMed ID: 29532212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.
    Moncrieffe H; Hinks A; Ursu S; Kassoumeri L; Etheridge A; Hubank M; Martin P; Weiler T; Glass DN; Thompson SD; Thomson W; Wedderburn LR
    Pharmacogenet Genomics; 2010 Nov; 20(11):665-76. PubMed ID: 20827233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.
    Jekic B; Lukovic L; Bunjevacki V; Milic V; Novakovic I; Damnjanovic T; Milasin J; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Kovacevic L; Krajinovic M
    Eur J Clin Pharmacol; 2013 Mar; 69(3):377-83. PubMed ID: 22763757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
    Samara SA; Irshaid YM; Mustafa KN
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.
    Boughrara W; Benzaoui A; Aberkane M; Moghtit FZ; Dorgham S; Lardjam-Hetraf AS; Ouhaibi-Djellouli H; Teixeira EP; Boudjema A
    Inflamm Res; 2017 Jun; 66(6):505-513. PubMed ID: 28299396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.
    Derambure C; Dzangue-Tchoupou G; Berard C; Vergne N; Hiron M; D'Agostino MA; Musette P; Vittecoq O; Lequerré T
    Arthritis Res Ther; 2017 May; 19(1):109. PubMed ID: 28545499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.